Product Images Doxorubicin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Doxorubicin Hydrochloride NDC 25021-207 by Sagent Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
dox01 0013 01
dox01 0013 02
Hazard Ratio (HR) is a statistical measure used in clinical trials to compare the probability of an event occurring in different treatment groups. The following text provides information on the hazard ratios observed in several trials, including NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. It also mentions that doxorubicin (DOXO) showed better results than CMF in six studies, but in one study, DOXO was found to be worse than CMF, with a boundary of non-inferiority with CMF at 1.06 (75% of CMF effect retained).*
dox01 0013 03
The given text mentions different trials and their corresponding hazard ratios for the comparison of Doxo (a type of chemotherapy) with CMF (Cyclophosphamide, Methotrexate, and Fluorouracil). However, the text is incomplete and does not provide enough information to generate a useful description.*
dox01 0013 04
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.